Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 11, 1997, Pages 3071-3078

  Scarabin, Pierre Yves ^a   Alhenc Gelas, Martine ^a   Plu Bureau, Geneviève ^a   Taisne, Pascale ^a   Agher, Rachid ^a   Aiach, Martine ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Hemostasis; Hormone replacement therapy; Menopause

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; D DIMER; ESTROGEN; FIBRINOGEN; PEPTIDE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE; PROTEIN C; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031443428     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.11.3071     Document Type: Article

References (14)

1. Lerner SJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-390.
2. Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth, WT, Weiss N, Wagner EH, Prentice R, Furberg CD. A review of association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 1993;153:1421-1427.
3. Grodstein F, Stampfer MJ, Manson JE, Speizer FE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:1303-1309.
4. Devor M, Barren-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med. 1992;92:275-282.
5. Guetta V, Cannon III RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation. 1996;93:1928-1937.
6. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atheroslerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
7. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1589-1592.
8. Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 ng or 30 μg of oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost. 1995;74:928-32.
9. The Coronary Drug Project Research Group. The coronary drug project: initial findings leading to modifications opf its research protocol. JAMA. 1970;214:1303-1313.
10. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-80.
11. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
12. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
13. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodart C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 1986;62:536-541.
14. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993;70:584-587.